Myopia and Presbyopia Treatment Market Share

Asia Pacific Market Insights

The APAC presbyopia and myopia treatment market is anticipated to grow strongly by maintaining the market share of 32.5% at a CAGR of 8.5% through 2035. The region is influenced by rising patient volumes, an aging population, and government spending in the healthcare sector. According to the data of the NLM report of August 2025, Myopia is an international epidemic, and about 80% of population among people aged over 20 years in East Asia population are affected. Advances in laser treatments, drug research, and tele-ophthalmology platforms are transforming patients' accessibility and administration of treatment.

China commands the largest market share of the market in the APAC region and will be estimated to account for a revenue share of 29.2% by 2035. According to the NLM report in May 2024, CNY 1 billion is utilized to enhance the accessibility of eye care services in rural regions. China has made achievements in preventing and treating blindness. Also, in 2023, many individuals have received myopia and presbyopia treatment due to the increased screen usage and the aging population.

Optical Instruments and Appliances Export in 2023

Source: WITS, 2023

North America Market Insights 

North America is the fastest-growing region in the myopia and presbyopia treatment market and is expected to hold a significant share by 2035. The market is driven by the favorable reimbursement policies, innovation in pharmacological therapies, and high procedure volumes. The prevalence of myopia in North America is estimated to be up to 42% in children ages 10 to 15 years. The U.S. market is the revenue anchor and is mainly driven by the Medicare and Medicaid expansions. The need for therapy is increasing increased to the rising incidence of visual diseases, which are connected to aging populations and digital screen exposure.

The myopia and presbyopia treatment market in the U.S. is fueled by the systemic reforms of Medicaid and Medicare. The National Eye Institute in May 2024 reports that refractive correction enhances the vision for 150 million Americans. R&D spending focuses on enhanced EDOF/trifocal optics, topical pharmacologic agents for presbyopia/myopia, and stepped-care delivery models that combine optometry and ophthalmology. The U.S. market stands as a global growth driver due to the benefits of emerging therapies and regulatory policies under the FDA for treatments concerning vision.

Europe Market Insights

The Europe myopia and presbyopia treatment market are growing and is expected to hold a considerable share by 2035, with the region's aging population, greater exposure to screens, and government healthcare policies. The rising incidence of uncorrected refractive errors among the elderly and youth populations has led to the prioritization of vision correction therapy. As per the NLM report in June 2025, the cost for myopia treatment in the traditional method is US$32,492/US$22,606. Patterns of digital eye strain and myopia development in children have set in motion early intervention programs in Germany, France, and the UK.

Germany dominates the myopia and presbyopia treatment market in Europe and is expected to hold the extensive market share by 2035. Based on the OEC report in 2023, Germany exports ophthalmic instruments and appliances worth $1.23 billion 2023. The extensive compensation provided by Germany's statutory health insurance system for advanced remedial treatments encourages robust market activity from both domestic and international firms. Germany's statutory health insurance incentivizes uptake of innovative treatments, bolstering demand.